Semaglutide and Smoking: The Trial Enrolling People Who Don't Want to Quit

*This article covers registered clinical research, not treatment advice. Semaglutide is not approved for smoking cessation, tobacco use, cravings, or any addiction-related condition — its approved indications are type 2 diabetes and chronic weight management. Nothing here is a suggestion to start, stop, or change any medication, and no outcome of any trial described is known yet.*

---

The Short Answer

A registered Phase 4 clinical trial (NCT06986993) is testing whether once-weekly semaglutide changes smoking behavior in people with obesity — and it deliberately excludes anyone with an immediate desire to quit. That design choice is the story. By studying smokers who are not trying to stop, the trial isolates the drug's effect on the brain's reward circuitry from the motivation that confounds nearly every smoking study ever run.

What is known today is modest and honest: early human evidence suggests semaglutide reduces cigarette *craving* even though it has not yet been shown to reduce *cigarettes per day* (PMID: 42189538). Nothing is approved. The definitive readout is realistically 2028 or later. This article explains the mechanism, the design, and exactly where the evidence stands.

---

Why Some People Quietly Stop Enjoying Smoking on a GLP-1

Among the most common stories people tell about GLP-1 medications like semaglutide: food noise faded, and with it — sometimes — the pull of other habits. Drinks stopped sounding interesting. For some, cigarettes did too.

There is a biological reason this is plausible rather than coincidental. GLP-1 receptors are expressed in the ventral tegmental area and nucleus accumbens — the core of the brain's reward and motivation circuitry — and GLP-1 signaling appears to modulate dopamine responses to rewarding cues of all kinds, from food to drugs. Preclinical work shows GLP-1 receptor agonists reducing nicotine self-administration and reward-related behavior in animal models (PMID: 38663460; PMID: 42310968), and reviews of the shared neurobiology of obesity and substance use describe a converging picture: one receptor system, many reward inputs (PMID: 42184906).

We cover that mechanism in depth in our guide to food noise and the brain's reward system — including why "quieting" a reward signal is different from erasing a habit. Here, the relevant point is narrower: if the mechanism is real in humans, it should show up somewhere. Food cravings were the first place patients noticed. Tobacco is where the research community is now testing it.

---

The Trial Enrolling People Who Don't Want to Quit — and Why That Makes It Smarter

Registered on ClinicalTrials.gov as NCT06986993 — "Impact of Semaglutide Administration on Tobacco Use Behavior and Related Mechanisms Among Smokers With Obesity" — the study is Phase 4 (the drug is already approved; the *behavioral indication* is what is being tested), randomized, and placebo-controlled.

The eligibility criteria are what set it apart:

• ✦Adults with obesity (BMI 30 or higher) — so the study population matches the population actually prescribed GLP-1s for weight
• ✦Smoking more than 2 cigarettes per day — regular use, not social smoking
• ✦No immediate desire to quit tobacco — the deliberate, unusual part

That last criterion inverts the normal logic of smoking research. Nearly every pharmacotherapy study for smoking enrolls treatment-seeking smokers: people who want to quit, consent to quit, and are surrounded by researchers invested in them quitting. Any measured effect is then a blend of the drug and the motivation the enrollment process itself created. By excluding people with an immediate desire to quit, this trial removes that blend. If cigarette use falls in this group, there is no quit attempt to credit — the change would have to come from the drug or from the physiological changes it causes. That is what researchers mean when they say the motivation-free design "isolates the reward-pathway hypothesis."

It is also why you should read this trial's eventual results differently from cessation-trial headlines. The primary outcome is simply "cigarette smoking" — behavior, not quit rates.

Where the evidence actually stands: one small published trial

The motivation-free Phase 4 study has no results. But it is not the first human test. A Phase 2a randomized trial at an academic medical center (registered as NCT05530577, published in *JAMA Network Open* in 2026) enrolled 24 non-treatment-seeking adults — note the same design logic — consuming at least 5 cigarettes daily, and randomized them to nine weeks of low-dose semaglutide (capping at 1.0 mg) or placebo (PMID: 42189538).

The results were genuinely mixed, and the distinction matters:

• ✦No significant effect on the co-primary laboratory measures of smoking resistance or on weekly cigarettes per day
• ✦Significant reduction in cigarette craving over treatment weeks
• ✦Significant weight loss (expected — this was also, in effect, a weight study)
• ✦Hints of reduced withdrawal symptoms in exploratory analyses

A 24-person trial with a small dose cannot settle anything. But the pattern — craving moving before consumption does — is consistent with the mechanism story and is exactly the kind of signal a larger trial is designed to chase. Meanwhile, a large cross-sectional study of over 13,000 patients on GLP-1s found associations with reduced nicotine cravings and some patients reporting they had become ex-smokers after starting therapy — but that study design cannot establish causation (PMID: 41673636). Observational reports are where these hypotheses start, not where they end.

---

The Honest Trial Tracker

Check the registry before believing any headline about semaglutide and smoking. The reality as of this writing: one small published trial with mixed results, one motivation-free trial still enrolling, and nothing approved.

---

The Confound Honest Coverage Owes You

Here is the part that separates this article from hype content — and it cuts in both directions.

Smoking and body weight are physiologically entangled. Many smokers smoke partly to manage their weight; nicotine suppresses appetite and quitting typically causes weight gain. On a GLP-1, two things happen that could each reduce smoking *without* touching the reward system: weight loss itself, and nausea — the most common semaglutide side effect — which could plausibly blunt any consumptive behavior, cigarettes included.

The motivation-free design controls for motivation, not for this. If NCT06986993 eventually shows reduced smoking in its participants, an honest reading will have to ask how much of the effect is reward circuitry and how much is an obese person losing weight and feeling nauseated. That is not a gotcha; it is why the trial also measures "related mechanisms" — and why a null result on smoking despite strong weight loss would itself be informative. Any future headline that reads "semaglutide cures smoking" without addressing the weight confound is telling you the writer did not read the trial design.

---

What This Is Not

Plainly, because it needs saying in every conversation on this topic:

• ✦Semaglutide is not approved for smoking cessation or any craving or addiction indication. Not for tobacco, not for alcohol, not for cannabis. Its approved uses are type 2 diabetes and chronic weight management.
• ✦No result exists yet for the motivation-free trial. It is recruiting, small (n≈40), and untouched by posted results since its last registry update in August 2025.
• ✦The best current randomized evidence found no significant reduction in cigarettes per day. If someone tells you GLP-1s are a quitting tool, that claim is running ahead of the data.
• ✦If quitting smoking is your goal, evidence-backed options exist: behavioral counseling combined with varenicline, bupropion, or nicotine replacement therapy. Bupropion in particular is FDA-approved for both depression and smoking cessation — a different drug with an entirely different evidence base, which we cover in our guide to bupropion and weight.

If you are considering a GLP-1 for weight or metabolic health and you also smoke, that is a conversation worth having with a licensed prescriber — ideally one who knows both literatures and will not promise you either outcome.

---

The Bigger Picture: One Drug Class, Many Habit Questions

The tobacco trial is not an isolated curiosity. It sits in a widening cluster of registered research asking whether GLP-1s modulate reward-driven behavior generally: a NIDA-funded trial of tirzepatide for cannabis use disorder is underway, and a separate research track is examining alcohol craving. The shared mechanism — GLP-1 receptors in the mesolimbic reward pathway — is the reason one drug class keeps showing up in this company.

None of this is an approved treatment yet. All of it is worth understanding now, while the honest answer to "does it work?" is still "the trials that would know haven't finished."

---

Frequently Asked Questions

Is semaglutide approved for smoking cessation? No. Its approved indications are type 2 diabetes and chronic weight management. Every smoking- or craving-related use is investigational.

Why would a trial enroll smokers who don't want to quit? To remove the motivation confound. If people who are not trying to quit smoke less on the drug, quit attempts can't explain it — the motivation-free design isolates the drug's biological effect.

Did any semaglutide smoking trial show results yet? One small one: a 24-participant Phase 2a trial (published 2026, PMID: 42189538) found significantly reduced craving and weight, but no significant reduction in cigarettes per day. The motivation-free Phase 4 trial (NCT06986993) has no results; readout is realistically 2028 or later.

Could weight loss or nausea explain any smoking reduction? Possibly, yes. Weight loss and GLP-1 nausea could each reduce smoking through mechanisms unrelated to reward circuitry. The motivation-free design does not control for this confound.

Should I take semaglutide to cut back on smoking? No. There is no approved indication for it, no dosing guidance, and the best current randomized trial found no significant reduction in cigarettes per day. Evidence-backed cessation treatments exist; use those, and make any GLP-1 decision with a licensed prescriber.

When will we know if semaglutide affects smoking? NCT06986993 lists estimated completion in mid-2028, with no results posted as of October 2026. Registry timelines slip and trials sometimes go inactive, so treat the date as a plan, not a promise.

---

Evidence Box

• ✦NCT06986993 — ClinicalTrials.gov registration. "Impact of Semaglutide Administration on Tobacco Use Behavior and Related Mechanisms Among Smokers With Obesity." Phase 4, randomized, placebo-controlled; requires BMI ≥30, >2 cigarettes/day, and no immediate desire to quit. Recruiting; ~40 participants estimated; est. completion June 2028; last registry update August 2025; no results posted. Verified against the registry at the time of writing.
• ✦PMID: 42189538 — Hendershot et al., *JAMA Network Open*, 2026. "Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial." Phase 2a, n=24 non-treatment-seeking adults (NCT05530577); no significant change in cigarettes/day or laboratory smoking resistance; significant reductions in craving and body weight.
• ✦PMID: 38663460 — Herman & Schmidt, *Physiology & Behavior*, 2024. "Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence." Review of preclinical evidence that GLP-1R agonists attenuate nicotine taking and seeking and prevent withdrawal-related weight gain.
• ✦PMID: 42310968 — Rahmadi et al., *Behavioural Neurology*, 2026. Animal study showing liraglutide attenuated nicotine reward-related behavior via orexin and glucagon pathway modulation — the mechanistic plausibility layer, preclinical only.
• ✦PMID: 42184906 — Lista et al., *Pharmacology, Biochemistry, and Behavior*, 2026. "GLP-1 receptor agonists at the crossroads of obesity and addiction." Narrative review of shared reward neurobiology; notes evidence limited by small samples and short follow-up.
• ✦PMID: 41967661 — Hendershot et al., *Biological Psychiatry*, 2026. "Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists for Smoking Cessation." Expert review positioning GLP-1s as promising but unproven; notes post-cessation weight-gain prevention as a distinct research question.
• ✦PMID: 41673636 — Alsaleh et al., *BMC Public Health*, 2026. Cross-sectional study of 13,232 patients on GLP-1s; associations with reduced nicotine cravings and some ex-smoker reports — observational, cannot establish causation.

---

Talk to a Physician-Led Program

If you are on — or considering — a GLP-1 medication and have questions that go beyond weight: how it interacts with your other habits, health conditions, or goals, those questions deserve a real clinical conversation with a licensed provider who knows your history. Our physician-led GLP-1 program exists for exactly that.

---

*LuxeFit Wellness is a virtual-only clinic serving patients nationwide. This content is educational only and does not constitute medical advice. Semaglutide is not approved for smoking cessation or any craving-related indication; the trials described are investigational with no results (or, in the one published small trial, mixed results that do not establish semaglutide as a cessation aid). No content here diagnoses, treats, or replaces care from a qualified clinician. Do not start, stop, or change any medication without your licensed prescriber.*

*You built it. We optimize it.*

Published by LuxeFit Wellness — physician-led GLP-1 and peptide therapy. Read the LuxeFit Wellness brand guide for programs, pricing, and how it works.

This article is for educational purposes only and does not constitute medical advice. Information on this website should not be used to diagnose, treat, or prevent any medical condition. Consult with a licensed physician before starting any new therapy.